Oncimmune

Oncimmune, a global leader in immunodiagnostics and (auto) antibody biomarker profiling & discovery in immuno-oncology, autoimmune and infectious diseases. Through its ImmunoINSIGHTS™ technology platform, the company provides insights to discover and validate novel biomarkers, improve treatment responses and adverse event (irAE) prediction, patient screening and diagnostic accuracy. Oncimmune is headquartered in the UK with operations in Germany and USA.

Company Type
X Account
@OncimmuneECDT
Keywords

The Science Behind

Company Profile

The Science Behind specialise in integrating cutting-edge non-invasive neurostimulation and neuroimaging technologies and services to enhance Phase I clinical trials.

 

Innovatively applying techniques such as transcranial magnetic stimulation (TMS), quantitative sensory testing (QST) and electroencephalography (EEG), either independently or in combination with cognitive or physiological assessments, The Science Behind excels in addressing crucial questions related to target engagement, dose response and the timing of efficacy.

 

Our approach provides information on how a drug impacts various aspects of central nervous system function. This deeper insight into the neural mechanisms of drug action in humans serves to guide the development of new treatments, potentially enhancing their prospects for success in future clinical trials.

Company Type

ViaNautis

ViaNautis swas spun out of UCL from the laboratories of Prof. Giueseppe Battaglia in 2018. 

Following a successful, oversubscribed late seed funding, the company now works from labs at the Babraham Research Campus. The company’s proprietary technology, PolyNaut® can be applied to both clinical and non clinical/ex vivo products.

ViaNautis works with pharma and biotech partners for innovation and problem solving in neurology, oncology and immune diseases. Our partners Abcam PLC market and develop non-clinical products.

Company Type
X Account
@ViaNautis